Lisheng Pharmaceutical released its 2026 semi-annual report. In the first half, it achieved operating revenue of 642 million yuan, net profit attributable to the parent of 78.326 million yuan, and net profit excluding non-recurring gains and losses of 67.042 million yuan. The company said the year-on-year decline in net profit attributable to the parent was mainly due to the high base of non-recurring income such as large investment gains in the same period last year, while the core pharmaceutical main business maintained a stable operating trend. As of the end of June 2026, the company's asset-liability ratio was only 15.50 percent, with no interest-bearing debt pressure, and its comprehensive gross margin remained at 55.69 percent. Cumulative cash dividends since listing have reached 1.492 billion yuan. The company continues to advance consistency evaluation of generic drugs and the development of new product projects, strictly implements quality management across the full drug lifecycle, and ensures stable supply of classic products.
Tianjin Lisheng Pharmaceutical Co LtdNet profit declined due to high base of non-recurring investment gains, but core pharma business stable; mixed financial results.
